Ligand Pharmaceuticals: Behind the $248 Million Institutional Bet on Biotech Royalty Model
Ligand Pharmaceuticals (LGND), biyofarmasötik şirketlerin late-stage klinik geliştirme programlarını finanse etmek ve desteklemek için royalty modelle
Ligand Pharmaceuticals (LGND) has entered the market as a leading platform for royalty models that finance and support late-stage clinical development programs for biopharmaceutical companies. With 34% and 60% revenue growth in recent quarters, the company is expected to deliver 8% sales and 14% EPS growth in 2026. Institutional investors are driving LGND toward its 326.63 buy point, supported by a 1.7 up/down volume ratio and $248 million in acquisitions. Captain Rıza Deniz: This move reflects the growing popularity of royalty models in the biopharmaceutical sector. LGND's success could prompt other biotech firms to reassess their royalty strategies.
Related News & Analysis
View All →
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Inertia Enterprises Cuts Fusion Fuel Loading to Hours, Shaking the Energy Market
Patreon Unveils 30 New Features to Revolutionize Creator Ecosystem
Latest Market News
All News →Rising Yields Threaten to Burst the Stock-Market Bubble: How Markets Will React
Human Capital Resilience in the Age of AI: Implications for Financial Markets
![[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş.
Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu](/_next/image?url=%2Fuploads%2Fkap-default.png&w=3840&q=75)
[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu
Turkey Cuts Inflation Target from 75–80% to 30%: Bolat’s Bold Move
Hyperliquid Goes to the US: Regulatory and Market Shockwaves